{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:14:49Z","timestamp":1790309689943,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jhep.2014.08.021","type":"journal-article","created":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T05:30:44Z","timestamp":1408771844000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy"],"prefix":"10.1016","volume":"62","author":[{"given":"Patrick","family":"Marcellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Wursthorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Fainboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Trylesinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Naoumov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.08.021_b0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.021_b0010","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.021_b0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2893.2006.00810.x","article-title":"Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion","volume":"14","author":"Chu","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.08.021_b0020","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1053\/j.gastro.2007.08.039","article-title":"Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"133","author":"Chu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.021_b0025","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.021_b0030","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.021_b0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.08.021_b0040","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.021_b0045","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.021_b0050","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.021_b0055","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.08.021_b0060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.08.021_b0065","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3years of telbivudine treatment in hepatitis B e antigen-positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.021_b0070","unstructured":"Division of AIDS. Table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992. Available from URL: http:\/\/rsc.tech-res.com\/safetyandpharmacovigilance\/gradingtables.aspx [Accessed October 1, 2012]."},{"key":"10.1016\/j.jhep.2014.08.021_b0075","unstructured":"Wursthorn K, Jung M, Manns M, Bao W, Wedemeyer W, Avila C. Quantitative serum HBeAg monitoring during telbivudine treatment corresponds with virological outcomes. Poster 1011. In: Presented at 45th annual meeting of the European Association for the Study of the Liver (EASL). April 14\u201318, 2010, Vienna, Austria."},{"key":"10.1016\/j.jhep.2014.08.021_b0080","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","article-title":"High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study","volume":"50","author":"Moucari","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.021_b0085","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1212\/WNL.37.10.1663","article-title":"Chronic relapsing demyelinating polyneuropathy associated with hepatitis B infection","volume":"37","author":"Inoue","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2014.08.021_b0090","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","article-title":"Side effects of long-term oral antiviral therapy for hepatitis B","volume":"49","author":"Fontana","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.08.021_b0095","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","article-title":"Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B","volume":"51","author":"Fleischer","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.021_b0100","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/S0168-8278(09)60909-0","article-title":"Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database","volume":"50","author":"Goncalves","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.08.021_b0105","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.00088-07","article-title":"Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B","volume":"51","author":"Kaymakoglu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.08.021_b0110","first-page":"CR56","article-title":"Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study","volume":"15","author":"Papadopoulos","year":"2009","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jhep.2014.08.021_b0115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814006072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814006072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T10:51:53Z","timestamp":1538304713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814006072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0168827814006072"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.08.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}